|
Fund Overview
Quote
Performance
|
Chart
Charting
Compare to:
|
Top News
More News
The Week Ahead In Biotech: FDA Decisions, Johnson & Johnson Among Big Pharma Earnings
October 13, 2019
Biotech stocks continued to languish for a third straight week. Negative broader market sentiment and company-specific weakness weighed ... Read More
from Benzinga
Stock Market Theme - Collect $200 Or Go Directly To Jail
October 13, 2019
The market feels like an X rated version of Monopoly, only instead of buying and trading properties, we are buying and trading headlines. Buy or trade it correctly and you can easily collect $200. Do... Read More
from Blogs - TalkMarkets
VC Money Is Flowing Into Biotechs
October 11, 2019
Venture capitalists are pouring cash into U.S. biotechs at a rate set to replicate 2018’s record deal count, according to ... Read More
from Benzinga
The Daily Biotech Pulse: Therapix Extends Merger Deadline, Five Prime Restructures, Gilead-Galapagos Rheumatism Drug Readout
October 11, 2019
The following is aroundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech ... Read More
from Benzinga
These battered biotech stocks are now buying opportunities as Elizabeth Warren climbs in the polls
October 11, 2019
Sen. Elizabeth Warren’s health-care reform crusade is rattling biotech investors — but that’s not the industry’s only problem, writes Michael Brush. Read More
from MarketWatch
Salmon on Ice; Is it Time to Buy China & Sell the US?
October 11, 2019
The bigger theory on this hedge is that ultimately, China outperforms the U.S. regardless of the trade outcome. Read More
from Blogs - TalkMarkets
The Daily Biotech Pulse: UCB To Buy Ra Pharma, Reata Reacquires Rights To Nrf2 Activators From AbbVie, BioNTech IPO
October 10, 2019
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting ... Read More
from Benzinga
The Daily Biotech Pulse: FDA Approves Clinuvel Drug, Aclaris Files Patent Lawsuit Against Taro, Viela Out-Licenses Autoimmune Disorder Drug
October 09, 2019
The following is aroundup of top developments in the biotech space over the last 24 hours. None of the NYSE or ... Read More
from Benzinga
Analysts See 40% Upside For The Holdings of IBB
October 08, 2019
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... Read More
from ETF Channel
The Daily Biotech Pulse: D-Day For Clinuvel, Qiagen Warns Of Q3 Shortfall, Prevail Announces Gene Therapy Collaboration
October 08, 2019
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting ... Read More
from Benzinga
Noteworthy ETF Outflows: IBB, CELG, GILD, ILMN
October 07, 2019
Symbols mentioned in this story: IBB, CELG, GILD, ILMN Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These... Read More
from ETF Channel
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.